Related references
Note: Only part of the references are listed.
Article
Immunology
Taisei Masuda et al.
Summary: This study evaluated the safety and immunogenicity of mRNA-1273 vaccine in healthy Japanese participants. The results showed that two doses of 100 μg mRNA-1273 administered 28 days apart demonstrated an acceptable safety profile and induced significant anti-SARS-CoV-2 immune responses in a Japanese population aged >= 20 years.
Article
Immunology
Laurence Chu et al.
Summary: The study evaluated the safety and immunogenicity of the mRNA-1273 vaccine in healthy adults, showing significant immune responses to SARS-CoV-2 with acceptable safety profile. This vaccine induced higher antibody levels at a 100 mg dose, confirming its immunogenicity and safety for use in a 2-dose regimen.
Article
Multidisciplinary Sciences
Miwa Haranaka et al.
Summary: The interim analysis of the ongoing study of the BNT162b2 vaccine in healthy Japanese adults showed that it has an acceptable safety profile and induces a robust immune response, regardless of age. The participants mainly experienced mild to moderate local reactions and no serious adverse events, with good antibody induction one month after the second dose.
NATURE COMMUNICATIONS
(2021)
Review
Medicine, General & Internal
Matthew J. Page et al.
Summary: The PRISMA statement was designed to help systematic reviewers transparently report the purpose, methods, and findings of their reviews. The updated PRISMA 2020 statement includes new reporting guidance, a 27-item checklist, an abstract checklist, and revised flow diagrams for reviews.
BMJ-BRITISH MEDICAL JOURNAL
(2021)
Article
Medicine, General & Internal
H. M. El Sahly et al.
Summary: The mRNA-1273 vaccine demonstrated high efficacy in preventing COVID-19 illness and severe disease, with more than 5 months of protection and a good safety profile, including protection against asymptomatic infection.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Medicine, General & Internal
S. J. Thomas et al.
Summary: BNT162b2 vaccine remains highly effective and safe over the course of 6 months post-vaccination, with efficacy rates ranging from 86% to 100% across different demographics and risk factors for Covid-19. The vaccine also shows a high efficacy against severe disease, with particularly promising results observed in South Africa against the B.1.351 variant.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Review
Infectious Diseases
Musha Chen et al.
Summary: A systematic review and meta-analysis found that the safety and tolerance of current COVID-19 vaccine candidates are acceptable for mass vaccination, with inactivated COVID-19 vaccines candidates having the lowest reported adverse events following immunization (AEFI). Long-term surveillance of vaccine safety is required, especially among elderly people with underlying medical conditions.
INFECTIOUS DISEASES OF POVERTY
(2021)
Review
Immunology
Yu-Jing Fan et al.
Summary: This systematic review and meta-analysis compared the safety and efficacy of COVID-19 vaccines, finding that mRNA vaccines were more associated with serious adverse events, while two doses of mRNA vaccines were most effective in reducing the risk of SARS-COV-2 infection. All vaccines were effective in reducing the risk of severe infection.
Review
Virology
Feng He et al.
JOURNAL OF MEDICAL VIROLOGY
(2020)
Article
Critical Care Medicine
Emily C. Zabor et al.
Article
Medicine, General & Internal
Edward E. Walsh et al.
NEW ENGLAND JOURNAL OF MEDICINE
(2020)
Article
Health Care Sciences & Services
Amelia J. Averitt et al.
NPJ DIGITAL MEDICINE
(2020)
